ncRNA basic information ncRNA ID: MI0000071 ncRNA Database: miRBase ncRNA Name: miR-17 ncRNA Type: miRNA ncRNA Expression: down-regulated ncRNA Method: RT-PCR ncRNA Target Gene: NCOA3 ncRNA Pathway: NA Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Drug Name: Taxol Drug Method: In this study, nuclear receptor coactivator 3 (NCOA3) was found to be significantly increased in taxol-resistant breast cancer tissues and cells. Moreover, overexpression of NCOA3 enhanced breast cancer cell resistance to taxol, whereas depletion of NCOA3 decreased taxol resistance. Subsequently, we investigated whether NCOA3 expression was regulated by miRNAs in breast cancer. By bioinformatics prediction in combination with the data of previous report, miR-17 and miR-20b were selected as the potential miRNAs targeting NCOA3. By real-time PCR analysis, we found that miR-17 and miR-20b were significantly reduced in taxol-resistant breast cancer tissues and cells. In addition, we provided some experimental evidences that miR-17 and miR-20b attenuated breast cancer resistance to taxol in vitro and in vivo models. Furthermore, by luciferase reporter assays, we further validated that both miR-17 and miR-20b directly binded the 3-untranslated region of NCOA3 mRNA and inhibited its expression in breast cancer cells. Finally, both miR-17 and miR-20b levels were found to be significantly negatively correlated with NCOA3 mRNA levels in breast cancer tissues. Together, our results indicated that loss of miR-17 and miR-20b enhanced breast cancer resistance to taxol by upregulating NCOA3 levels. Drug Response: resistant

Cancer basic information Cancer: breast cancer Tissue/Cell: cell line ( MCF-7, MDA-MB-231,MCF-7/Tax1, MCF-7/Tax2, 231/Tax1 and 231/Tax2)

Other information Title: Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3. Journal: Cell Death Dis Published: 2016 PubMed ID: 27831559